ISDA

Deposition Date 2020-09-29

Release Date 2021-02-10

Last Version Date 2024-10-16

Entry Detail

PDB ID:

7AJR

Keywords:

HYDROLASE

Title:

Virtual screening approach leading to the identification of a novel and tractable series of Pseudomonas aeruginosa elastase inhibitors

Biological Source:

Source Organism:

Pseudomonas aeruginosa (Taxon ID: 287)

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.75 Å

R-Value Free:

0.23

R-Value Work:

0.20

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Keratinase KP2
Chain IDs:A (auth: AAA)
Chain Length:301
Number of Molecules:1
Biological Source:Pseudomonas aeruginosa

UniProt ID:E3ULB4 Pfam ID:PF01447, PF02868

Ligand Molecules

RJB

SO4

Primary Citation

Virtual Screening Approach to Identifying a Novel and Tractable Series of Pseudomonas aeruginosa Elastase Inhibitors.

Leiris, S, Davies, D.T, Sprynski, N, Castandet, J, Beyria, L, Bodnarchuk, M.S, Sutton, J.M, Mullins, T.M.G, Jones, M.W, Forrest, A.K, Pallin, T.D, Karunakar, P, Martha, S.K, Parusharamulu, B, Ramula, R, Kotha, V, Pottabathini, N, Pothukanuri, S, Lemonnier, M, Everett, M.Show

Acs Med.Chem.Lett. 12 217 227 (2021)

PMID: 33603968 DOI: 10.1021/acsmedchemlett.0c00554

Abstact

Novel therapies are required to treat chronic bacterial infections in cystic fibrosis (CF) sufferers. The most common pathogen responsible for these infections is Pseudomonas aeruginosa, which persists within the lungs of CF sufferers despite intensive antibiotic treatment. P. aeruginosa elastase (also known as LasB or pseudolysin) is a key virulence determinant that contributes to the pathogenesis and persistence of P. aeruginosa infections in CF patients. The crucial role of LasB in pseudomonal virulence makes it a good target for the development of an adjuvant drug for CF treatment. Herein we discuss the discovery of a new series of LasB inhibitors by virtual screening and computer assisted drug design (CADD) and their optimization leading to compounds 29 and 39 (K i = 0.16 μM and 0.12 μM, respectively).

Legend

Protein

Chemical

Disease

Primary Citation of related structures